{"filing":{"accession_number":"0001104659-26-069206","cik":"0001509261","ticker":"RZLT","company_name":"Rezolute, Inc.","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"tm2616579d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1509261/000110465926069206/tm2616579d1_8k.htm"},"events":[{"id":7380,"run_id":6484,"accession_number":"0001104659-26-069206","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Rezolute issued a press release on June 2, 2026 announcing an interim update on its upLIFT study, a clinical trial. While the actual content of the update is not provided in this Item 7.01 disclosure (only boilerplate forward-looking statements and liability disclaimers are shown), interim clinical trial results can be material to investors assessing the company's pipeline and prospects. Without visibility into whether the update was positive, negative, or neutral, and lacking the substantive details, this is best classified as other_material rather than a more specific category.","company_name":"Rezolute, Inc.","ticker":"RZLT","filing_date":"2026-06-02","form":"8-K","submitted_at":null,"items":[{"id":3459,"accession_number":"0001104659-26-069206","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Rezolute issued a press release on June 2, 2026 announcing an interim update on its upLIFT study, a clinical trial. While the actual content of the update is not provided in this Item 7.01 disclosure (only boilerplate forward-looking statements and liability disclaimers are shown), interim clinical trial results can be material to investors assessing the company's pipeline and prospects. Without visibility into whether the update was positive, negative, or neutral, and lacking the substantive details, this is best classified as other_material rather than a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:09:57.330374+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3459,"accession_number":"0001104659-26-069206","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Rezolute issued a press release on June 2, 2026 announcing an interim update on its upLIFT study, a clinical trial. While the actual content of the update is not provided in this Item 7.01 disclosure (only boilerplate forward-looking statements and liability disclaimers are shown), interim clinical trial results can be material to investors assessing the company's pipeline and prospects. Without visibility into whether the update was positive, negative, or neutral, and lacking the substantive details, this is best classified as other_material rather than a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:09:57.330374+00:00","company_name":"Rezolute, Inc.","ticker":"RZLT","filing_date":"2026-06-02"}]}